Emergent Biosolutions Inc (NYSE: EBS) kicked off on Tuesday, down -9.02% from the previous trading day, before settling in for the closing price of $11.97. Over the past 52 weeks, EBS has traded in a range of $1.42-$15.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 10.59% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 82.99%. With a float of $52.06 million, this company’s outstanding shares have now reached $52.20 million.
In an organization with 1600 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 38.98%, operating margin of -8.78%, and the pretax margin is -15.42%.
Emergent Biosolutions Inc (EBS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Emergent Biosolutions Inc is 3.91%, while institutional ownership is 54.62%. The most recent insider transaction that took place on Nov 12 ’24, was worth 294,250. Before that another transaction happened on Nov 11 ’24, when Company’s Director proposed sale 14,287 for $11.77, making the entire transaction worth $168,158.
Emergent Biosolutions Inc (EBS) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.77 earnings per share (EPS), lower than consensus estimate (set at -0.19) by -0.58. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.5 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 82.99% per share during the next fiscal year.
Emergent Biosolutions Inc (NYSE: EBS) Trading Performance Indicators
Take a look at Emergent Biosolutions Inc’s (EBS) current performance indicators. Last quarter, stock had a quick ratio of 1.47. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.52. Likewise, its price to free cash flow for the trailing twelve months is 4.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.10, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach 1.75 in one year’s time.
Technical Analysis of Emergent Biosolutions Inc (EBS)
Let’s dig in a bit further. During the last 5-days, its volume was 2.61 million. That was inferior than the volume of 3.39 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 70.84%. Additionally, its Average True Range was 0.93.
During the past 100 days, Emergent Biosolutions Inc’s (EBS) raw stochastic average was set at 57.26%, which indicates a significant increase from 55.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 101.92% in the past 14 days, which was lower than the 157.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.57, while its 200-day Moving Average is $6.22. However, in the short run, Emergent Biosolutions Inc’s stock first resistance to watch stands at $11.48. Second resistance stands at $12.07. The third major resistance level sits at $12.50. If the price goes on to break the first support level at $10.47, it is likely to go to the next support level at $10.04. The third support level lies at $9.45 if the price breaches the second support level.
Emergent Biosolutions Inc (NYSE: EBS) Key Stats
The company with the Market Capitalisation of 590.06 million has total of 54,184K Shares Outstanding. Its annual sales at the moment are 1,049 M in contrast with the sum of -760,500 K annual income. Company’s last quarter sales were recorded 293,800 K and last quarter income was 114,800 K.
